The company confirmed the sale of approximately 64.6 million ordinary shares at a price of $2.1667 per share. This news sent the stock climbing to $10.36 during early Tuesday sessions, reflecting investor confidence in the clinical-stage biotech's liquidity position.

CEO Backing and Capital Structure

A substantial portion of the financing originates from within the company’s leadership. According to the announcement, the private placement includes a $55 million investment from entities controlled by Chief Executive Yang Lu. This significant commitment by the CEO suggests a strong internal conviction regarding the firm's long-term clinical pipeline and commercial prospects.

The total $140 million raise provides Adlai Nortye with a robust runway to advance its current development programs. While specific use of proceeds was not detailed in the initial filing, such capital raises in the biotech sector typically fund late-stage clinical trials and research and development initiatives.